Ipca Laboratories (NSE:IPCALAB) DeferredTaxAndRevenue: ₹0 Mil (As of Mar. 2026)


NSE:IPCALAB Ipca Laboratories Ltd NSE:IPCALAB
92 GF Score
Price ₹1,787.90
GF Value ₹1,602.79
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ipca Laboratories DeferredTaxAndRevenue?

Ipca Laboratories NSE:IPCALAB +0.99% 92 DeferredTaxAndRevenue is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:IPCALAB with a GF Score™ of 92/100 and a GF Value™ of ₹1,602.79 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Ipca Laboratories's current deferred tax and revenue for the quarter that ended in Mar. 2026 was ₹0 Mil.

Ipca Laboratories DeferredTaxAndRevenue Related Terms

Ipca Laboratories DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Ipca Laboratories's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipca Laboratories DeferredTaxAndRevenue Chart

Ipca Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ipca Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:IPCALAB
92GF Score
Ipca Laboratories Ltd NSE:IPCALAB
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of ₹0 Mil mean?
Ipca Laboratories (NSE:IPCALAB) has a DeferredTaxAndRevenue of ₹0 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Ipca Laboratories.
Is Ipca Laboratories' DeferredTaxAndRevenue too high?
Ipca Laboratories' current DeferredTaxAndRevenue is ₹0 Mil. Overall, Ipca Laboratories has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' DeferredTaxAndRevenue compare to ZTS and UTHR?
Ipca Laboratories' DeferredTaxAndRevenue of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Drug Manufacturers company?
A good DeferredTaxAndRevenue depends on the Drug Manufacturers industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Ipca Laboratories. Ipca Laboratories's current DeferredTaxAndRevenue is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,602.79, compared to a current price of ₹1,787.90 — trading 11.5% above its estimated fair value. The current DeferredTaxAndRevenue is ₹0 Mil. Ipca Laboratories' overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current DeferredTaxAndRevenue is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?

Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued. The current stock price of ₹1,787.90 is trading 11.5% above its estimated GF Value™ of ₹1,602.79. GuruFocus considers Ipca Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:IPCALAB:

  • DeferredTaxAndRevenue: ₹0 Mil
  • GF Value™: ₹1,602.79 vs. price of ₹1,787.90 (11.5% above fair value)
  • GF Score™: 92/100 with 5 warning signs

No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipca Laboratories Business Description

Other Exchanges 524494:India
Address No. 48, 123 AB, 125 & 126 Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
92GF Score

Get the complete analysis for NSE:IPCALAB

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,787.90
Price
₹1,602.79
GF Value